EA201270607A1 - Аденовирус обезьян и способы его использования - Google Patents

Аденовирус обезьян и способы его использования

Info

Publication number
EA201270607A1
EA201270607A1 EA201270607A EA201270607A EA201270607A1 EA 201270607 A1 EA201270607 A1 EA 201270607A1 EA 201270607 A EA201270607 A EA 201270607A EA 201270607 A EA201270607 A EA 201270607A EA 201270607 A1 EA201270607 A1 EA 201270607A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monkey
adenovirus
methods
provides
human
Prior art date
Application number
EA201270607A
Other languages
English (en)
Inventor
Джейсон Галл
Дуглас Браф
Кристоф Кал
Дункан МакВей
Original Assignee
Генвек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Генвек, Инк. filed Critical Генвек, Инк.
Publication of EA201270607A1 publication Critical patent/EA201270607A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение представляет способы репродукции аденовируса обезьян в клетке, в том числе клетке человека, содержащей один или несколько продуктов генов, выделенных из аденовируса человека. Кроме того, изобретение представляет способы репродукции, в которых аденовирус обезьян содержит нуклеотидную последовательность, кодирующую продукт гена аденовируса человека. Кроме того, настоящее изобретение представляет аденовирус обезьян, включая аденовирус обезьян, дефектный по репликации, полученный с помощью таких способов репродукции.
EA201270607A 2009-11-09 2010-11-09 Аденовирус обезьян и способы его использования EA201270607A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25934309P 2009-11-09 2009-11-09
PCT/US2010/055991 WO2011057248A2 (en) 2009-11-09 2010-11-09 Simian adenovirus and methods of use

Publications (1)

Publication Number Publication Date
EA201270607A1 true EA201270607A1 (ru) 2012-09-28

Family

ID=43577533

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270607A EA201270607A1 (ru) 2009-11-09 2010-11-09 Аденовирус обезьян и способы его использования

Country Status (12)

Country Link
US (2) US9133248B2 (ru)
EP (2) EP2853266B1 (ru)
JP (2) JP5980117B2 (ru)
KR (1) KR20120139672A (ru)
CN (1) CN102770146B (ru)
AU (1) AU2010314842A1 (ru)
BR (1) BR112012010824A2 (ru)
CA (1) CA2779632C (ru)
EA (1) EA201270607A1 (ru)
IL (1) IL219492A0 (ru)
MX (1) MX2012005181A (ru)
WO (1) WO2011057248A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057248A2 (en) * 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
BR112014008284A2 (pt) 2011-10-05 2020-10-27 Genvec Inc. adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso
JP6757119B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
CN107937440A (zh) 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
CA3200425A1 (en) * 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
US10376549B2 (en) * 2015-01-20 2019-08-13 Adcure Biotechnologies, Llc. Detargeted adenovirus variants and related methods
US9982276B2 (en) * 2015-03-12 2018-05-29 Adcure Biotechnologies, Llc. Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use
BR112020007695A2 (pt) * 2017-10-31 2020-10-20 Janssen Vaccines & Prevention B.V. adenovírus e seus usos
WO2019118480A1 (en) 2017-12-11 2019-06-20 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
CN113637705B (zh) * 2021-08-19 2024-03-01 中国疾病预防控制中心病毒病预防控制所 猴1型腺病毒（SAdV-1）载体系统及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5962311A (en) 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2236912C (en) 1995-11-28 2006-04-25 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1997020575A1 (en) 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
HUP0002070A2 (hu) 1997-05-28 2000-10-28 Genvec, Inc. Alternatív módon célba juttatott adenovírus
AU8067698A (en) 1997-06-09 1998-12-30 Genvec, Inc. Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
US5944106A (en) 1997-08-06 1999-08-31 Halliburton Energy Services, Inc. Well treating fluids and methods
JP2003521221A (ja) 1998-02-11 2003-07-15 ジェンベク、インコーポレイティッド 有害ウイルス真核生物遺伝子導入ベクターの製造の為のベクター、細胞および方法
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
JP2003534806A (ja) 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US20030040100A1 (en) 2001-07-23 2003-02-27 Genvec, Inc. Cell for the propagation of adenoviral vectors
AU2002327380A1 (en) 2001-07-23 2003-03-18 Genvec, Inc. Cells and methods for propagating adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
EP1425045A4 (en) 2001-09-13 2004-11-10 Genvec Inc ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
SG2013034475A (en) * 2001-11-21 2016-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2477954C (en) * 2002-04-25 2012-07-10 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
MX347246B (es) * 2007-11-28 2017-04-19 Univ Pennsylvania Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
JP5882741B2 (ja) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
WO2011057248A2 (en) * 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use

Also Published As

Publication number Publication date
US20150329834A1 (en) 2015-11-19
US9133248B2 (en) 2015-09-15
US9586998B2 (en) 2017-03-07
WO2011057248A3 (en) 2011-09-15
JP2013509887A (ja) 2013-03-21
CN102770146A (zh) 2012-11-07
AU2010314842A1 (en) 2012-05-31
JP5980117B2 (ja) 2016-08-31
EP2853266B1 (en) 2018-01-31
US20120225470A1 (en) 2012-09-06
KR20120139672A (ko) 2012-12-27
CA2779632A1 (en) 2011-05-12
IL219492A0 (en) 2012-06-28
EP2498791B1 (en) 2014-12-24
CA2779632C (en) 2019-08-20
EP2498791A2 (en) 2012-09-19
EP2853266A1 (en) 2015-04-01
CN102770146B (zh) 2016-02-03
BR112012010824A2 (pt) 2018-03-06
JP6277213B2 (ja) 2018-02-07
WO2011057248A2 (en) 2011-05-12
JP2016146838A (ja) 2016-08-18
MX2012005181A (es) 2012-08-01

Similar Documents

Publication Publication Date Title
EA201270607A1 (ru) Аденовирус обезьян и способы его использования
CY1113713T1 (el) Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα
CY1119974T1 (el) Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης
PH12015502433A1 (en) Fgf21 mutants and uses thereof
CY1119509T1 (el) Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης
WO2008069906A3 (en) Digital expression of gene analysis
MX2010006576A (es) Composiciones y metodos para producir isopreno.
GB201020995D0 (en) Biological materials and uses thereof
CO6561839A2 (es) Alteracion genómica dirigida
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
WO2011047087A3 (en) Protein detection via nanoreporters
DK2152794T3 (da) Oxygen-fjernende molekyler, artikler indeholdende disse, og fremgangsmåde til deres anvendelse
UA104459C2 (ru) Антитела к fgfr3 и способы их применения
TN2011000161A1 (en) Fgf21 mutants and uses thereof
MY162737A (en) 4-1bb binding molecules
MX2009009598A (es) Reovirus que tienen secuencias modificadas.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MX2009007661A (es) Inhibidores de mek.
WO2012096579A3 (en) Paired end random sequence based genotyping
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
AR090318A1 (es) Lotes de adenovirus recombinantes con extremos terminales alterados
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2009149359A8 (en) Survival predictor for diffuse large b cell lymphoma